Regeneron's latest quarter shows sharp acceleration, with revenue up 36.3% year-over-year to $5.1B and gross margin expanding to 88.8%, suggesting operating leverage may be taking hold after a choppy 2025 to early 2026.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue and margins have trended sharply higher in the latest quarter, with gross margin reaching 88.8% and operating margin 40.0% in 2026Q3, although prior quarters showed uneven growth of 16.7% and 19.0%, suggesting the improvement may be lumpy rather than steady.
Regeneron focuses on discovering and developing medicines for serious medical conditions, indicating a robust pipeline of potential treatments.
The company maintains a dedicated Investor Relations website, showcasing transparency and engagement with stockholders and analysts.
As a long-standing biotech firm since 1988, Regeneron has established expertise in developing and commercializing innovative therapies.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 30, 2026 | $20.07+21.6% vs $16.51 | $5.1B+11.6% vs $4.6B |
Q3 2026 Jul 30, 2026 | $14.29+40.6% vs $10.16 | $4.3B+12.4% vs $3.8B |
Q2 2026 Apr 29, 2026 | $9.47+6.3% vs $8.91 | $3.6B+3.6% vs $3.5B |
Q1 2026 Jan 30, 2026 | $11.44+6.5% vs $10.74 | $3.9B+1.9% vs $3.8B |
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) EVP Joseph Larosa sold 4,466 shares of the firm's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the completion of the transaction, the executive vice president owned 38,906 shares of
Compass Financial Management LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 4,526.2% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,007 shares of the biopharmaceutical company's stock after acquiring an additional 2,942 shares during the
AIA Group Ltd cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 37.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,482 shares of the biopharmaceutical company's stock after selling 3,254 shares during the period. AIA Group Ltd's holdings
Bank Julius Baer and Co. Ltd Zurich boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 165.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,904 shares of the biopharmaceutical company's stock after
Benchmark REGN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Regeneron Pharmaceuticals, Inc. (REGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $904.35 | $93.17B | 19.82 | 0.99% | 28.51% | 15.07% | 0.38% | |
| $248.35 | $36.69B | 105.48 | 1.39% | 3.38% | 1.86% | — | |
| $547.09 | $138.85B | 35.12 | 9.57% | 30.61% | 20.08% | — | |
| $119.65 | $24.25B | 60.28 | 21.22% | 6.71% | 7.11% | — | |
| $56.03 | $10.83B | -567.68 | 12.87% | -0.52% | -0.31% | — | |
| $291.31 | $514.68B | 49.87 | 8.57% | 15.68% | — | 2.26% |
Regeneron Pharmaceuticals, Inc. (REGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Regeneron Pharmaceuticals, Inc. (REGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 30, 2026·SEC
Oct 6, 2026·SEC
Jul 30, 2026·SEC
Get notified when REGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Regeneron Pharmaceuticals, Inc. (REGN) stock FAQ — growth, dividends, profitability & financials explained
Regeneron Pharmaceuticals, Inc. (REGN) reported $16.90B in revenue over the trailing twelve months. Revenue was $14.34B in fiscal year 2025. That is 59414% more than the $24.1M of fiscal year 1996.
Regeneron Pharmaceuticals, Inc. (REGN) grew revenue by 18.6% over the trailing twelve months, compared with the twelve months before.
Yes. Regeneron Pharmaceuticals, Inc. (REGN) earned $4.82B in net income over the trailing twelve months (a 28.5% net margin).
Yes. Regeneron Pharmaceuticals, Inc. (REGN) pays a dividend that yields 0.38% at the current price, a small yield.
Regeneron Pharmaceuticals, Inc. (REGN) had a return on equity (ROE) of 15.1% over the trailing twelve months. That is above the market's typical 10-15%.
Regeneron Pharmaceuticals, Inc. (REGN) generated $3.59B in free cash flow over the trailing twelve months.
